Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)
August 2, 2021 06:08 PM EDTUpdated August 6, 01:22 PM
Deals

Sanofi buys mR­NA play­er Trans­late Bio for $3.2B. And the price fits a pop­u­lar range for biotech M&A

John Carroll

Editor & Founder

Sanofi CEO Paul Hud­son is dead se­ri­ous about his in­ten­tion to vault di­rect­ly in­to con­tention for the fu­ture of mR­NA vac­cines.

A year af­ter pay­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times